Home » Proprietary Adjuvant System Induces Improved Immune Response vs. Conventional Formulation

Proprietary Adjuvant System Induces Improved Immune Response vs. Conventional Formulation

Overview:

GlaxoSmithKline’s (GSK) candidate vaccine for the prevention of cervical cancer formulated with proprietary AS04 adjuvant system claims to have better immune response compared with the vaccine formulated with conventional aluminum salt adjuvant.

Author: GlaxoSmithKline | File Size: 117 KB | File Type: PDF

Find more white papers on Industry Developments

View all white papers »

More content on this topic:

  • Featured White Papers
  • White Papers by Topic
Process Operations
Automation & Control
Finishing & Packaging
Facilities & Support
Contract Services
Industry Developments